If you purchased or acquired securities in GSK between February 5, 2020 and August 14, 2022 and would like to discuss your ...

GSK PLC closed 21.63% short of its 52-week high of £18.24, which the company reached on May 16th.

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...